Darwin Wealth Management LLC Boosts Stock Holdings in Dyne Therapeutics, Inc. $DYN

Darwin Wealth Management LLC grew its position in Dyne Therapeutics, Inc. (NASDAQ:DYN) by 34.4% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 154,862 shares of the company’s stock after acquiring an additional 39,595 shares during the quarter. Darwin Wealth Management LLC owned about 0.09% of Dyne Therapeutics worth $2,808,000 as of its most recent SEC filing.

Several other hedge funds have also recently added to or reduced their stakes in the company. JPMorgan Chase & Co. grew its holdings in Dyne Therapeutics by 9.0% in the 3rd quarter. JPMorgan Chase & Co. now owns 3,365,245 shares of the company’s stock valued at $42,570,000 after buying an additional 278,466 shares in the last quarter. Aberdeen Group plc raised its holdings in shares of Dyne Therapeutics by 99.0% during the 4th quarter. Aberdeen Group plc now owns 1,108,145 shares of the company’s stock worth $21,675,000 after acquiring an additional 551,412 shares during the period. SG Americas Securities LLC acquired a new position in shares of Dyne Therapeutics during the 4th quarter valued at about $5,191,000. Clearbridge Investments LLC purchased a new stake in shares of Dyne Therapeutics in the fourth quarter valued at about $7,976,000. Finally, Fisher Asset Management LLC acquired a new stake in Dyne Therapeutics during the fourth quarter worth about $4,891,000. 96.68% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

DYN has been the topic of several recent analyst reports. Evercore set a $33.00 target price on shares of Dyne Therapeutics in a report on Friday, May 15th. Sanford C. Bernstein upped their price objective on Dyne Therapeutics from $23.00 to $24.00 and gave the company a “market perform” rating in a report on Wednesday, May 13th. TD Cowen assumed coverage on Dyne Therapeutics in a research report on Friday, June 26th. They issued a “buy” rating for the company. Weiss Ratings restated a “sell (d-)” rating on shares of Dyne Therapeutics in a research report on Monday, April 20th. Finally, Wall Street Zen raised Dyne Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Monday, July 6th. Two analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $34.17.

Dyne Therapeutics Stock Performance

Shares of DYN stock opened at $23.42 on Friday. The firm’s 50 day moving average price is $19.24 and its 200-day moving average price is $18.35. The company has a debt-to-equity ratio of 0.17, a quick ratio of 19.92 and a current ratio of 19.92. Dyne Therapeutics, Inc. has a one year low of $8.24 and a one year high of $25.00. The firm has a market cap of $3.87 billion, a P/E ratio of -7.27 and a beta of 1.06.

Dyne Therapeutics (NASDAQ:DYN) last posted its earnings results on Monday, May 11th. The company reported ($0.73) earnings per share for the quarter, beating the consensus estimate of ($0.77) by $0.04. During the same quarter last year, the company posted ($1.05) earnings per share. As a group, equities research analysts predict that Dyne Therapeutics, Inc. will post -3.02 EPS for the current year.

Insider Activity at Dyne Therapeutics

In other news, Director Jason P. Rhodes sold 480,240 shares of Dyne Therapeutics stock in a transaction on Monday, July 6th. The stock was sold at an average price of $22.79, for a total value of $10,944,669.60. Following the completion of the sale, the director directly owned 875,912 shares of the company’s stock, valued at approximately $19,962,034.48. The trade was a 35.41% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders acquired 9,000 shares of company stock worth $156,800 and sold 3,111,730 shares worth $64,079,704. 9.46% of the stock is currently owned by corporate insiders.

Dyne Therapeutics Profile

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.